Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer




Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers




AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

PRESS RELEASE

AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND POTENTIALLY OTHER CANCERS

• AB8939 is a promising drug candidate for refractory AML, especially for cases with poor prognoses such as complex karyotypes, MECOM rearrangements, and TP53 mutations
• AB8939 has dual action against both proliferating tumor cells (via tubulin disruption) and quiescent, resistant stem cells (via ALDH inhibition) making it a unique therapeutic agent
• Based on these findings, AB8939 is being evaluated in a Phase I/II clinical trial for relapsed or refractory AML

Paris, December 15, 2025, 6.30pm CET

AB Science SA (Euronext – FR0010557264 – AB) today announced the publication of a new article on the preprint platform bioRxiv. This article is entitled ‘Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug candidate for the treatment of refractory acute myeloid leukemia’ and is freely accessible online from the bioRxiv website [1].

Professor Olivier Hermine, President of AB Science’s Scientific Committee, member of the French Academy of Sciences and Head of the Hematology Department at Necker Hospital, commented: “Our preclinical research has identified AB8939 as a powerful compound with a novel dual mechanism of action, which holds potential for treating high-risk acute myeloid leukemia. The data indicate that AB8939 disrupts microtubule formation, a classic anti-cancer strategy, and inhibits ALDH enzymes, which are implicated in therapy resistance and the survival of leukemic stem cells. We demonstrated that AB8939 overcomes formidable drug resistance pathways, such as P-gp efflux, and is highly effective against patient-derived AML cells that are resistant to standard therapies. Most importantly, our work in advanced preclinical models shows that it can eradicate the leukemic stem cells that fuel this disease, a critical step toward preventing relapse. These robust findings provide a strong scientific rationale for the ongoing clinical trials and represent a tangible step toward developing a new, effective therapy for patients with high-risk and refractory AML.”

The key findings are as follows.

• AB8939 has a novel dual-targeting mechanism of action
  • Microtubule Destabilizer: It acts as a microtubule-targeting agent (MTA) by binding to the colchicine-binding site on β-tubulin. This interaction disrupts the microtubule network, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis (programmed cell death).
  • ALDH Inhibitor: Through reverse proteomics, aldehyde dehydrogenases (ALDH), specifically ALDH1 and ALDH2, were identified as secondary targets of AB8939. AB8939 is a potent inhibitor of these enzymes, which are often overexpressed in tumors and are associated with cancer stem cells, tumor progression, and resistance to therapy.
• AB8939 has potent and broad antiproliferative activity
  • AB8939 demonstrated strong and broad-spectrum antiproliferative activity against a wide variety of human cancer cell lines, with particularly high potency against hematopoietic cancers, with IC₅₀ values in the nanomolar range.
• AB8939 can overcome several major mechanisms of drug resistance in cancer cells
  • P-glycoprotein (P-gp) Efflux: Unlike many conventional chemotherapeutics (e.g., doxorubicin and vincristine), AB8939 is not a substrate for the P-gp efflux pump. This allows it to remain effective in cancer cells that overexpress P-gp, a common cause of multidrug resistance (MDR).
  • β3-tubulin Expression: The molecule retains its efficacy in cell lines with high expression of β3-tubulin, another factor linked to resistance against microtubule-targeting agents.
  • Chemoresistance in AML: It shows high cytotoxicity against AML patient blasts, including those resistant to standard-of-care agents such as cytarabine (Ara-C) and vincristine.
• In vivo evidence supporting the therapeutic potential of AB8939 in AML
  • In an Ara-C-resistant AML mouse model (MOLM-14), AB8939 treatment significantly inhibited tumor growth and increased survival rates.
  • In a patient-derived xenograft (PDX) model of high-risk AML (TG-LAM-75 with MECOM rearrangement), AB8939 monotherapy was effective, and its combination with azacitidine led to near-complete disease clearance with a manageable safety profile.
  • AB8939 effectively eradicated leukemic stem cells (LSCs) in an AML PDX model (TG-AML-36), suggesting that it could reduce the risk of disease relapse.

Clinical study AB18001

AB8939 is currently being evaluated in a Phase I/II clinical trial (AB18001, NCT05211570) in patients with refractory and relapsed AML. AB Science recently received regulatory approval to initiate the third stage of this study, which combines the molecule AB8939 with venetoclax for the treatment of acute myeloid leukemia [2].

The objective of the Phase 1 study was to determine the maximum tolerated dose (MTD) for different treatment cycles of AB8939.

• Stage 1: Determination of the MTD after three consecutive days of treatment with AB8939 alone.
• Stage 2: Determination of the MTD after 14 consecutive days of treatment with AB8939 alone.
• Step 3: Determination of the MTD after 14 consecutive days of treatment with AB8939 in combination with venetoclax.
• Stage 4: Determination of MTD after 14 consecutive days of treatment with AB8939 in combination with venetoclax and azacitidine.

The first two stages of Phase 1 were completed with 28 and 13 patients enrolled, respectively, and the MTD of AB8939 was determined after 3 consecutive days of treatment (21.3 mg/m² ) and after 14 consecutive days of treatment (21.3 mg/m²). The third stage now consists of evaluating the MTD after 14 consecutive days of treatment with AB8939 in combination with venetoclax, a standard treatment for AML.

Intellectual property protection until 2036 or even 2044 and orphan drug protection

AB8939 was discovered by AB Science, which retains full ownership of the intellectual property rights, reflecting AB Science’s priority to develop innovative drugs aimed at improving patients’ lives.

The composition of AB8939, including its use in the treatment of AML, is covered until 2026 by a patent granted in all geographical areas where AB8939 could be marketed, including Europe (patent EP 3253749), the United States (US 10,570,122), Canada (CA 2975644), China (CN 107531685), South Korea (KR 10-2544132), Japan (JP 6713000), Hong Kong (HK 1243700), Israel (IL 253779), Australia (AU 2016214283), Russia (RU 2758259), Brazil (BR 112017016883-9), Mexico (MX 377742), India (IN 480996), and South Africa (ZA 2017/05537).

A second patent application for medical use was filed to protect the use of AB8939 in the treatment of AML with specific chromosomal abnormalities. If this application is accepted, the protection for AB8939 will be extended until 2044 for these subpopulations of AML patients.

In addition to patent protection, AB8939 is eligible for regulatory data protection in numerous countries, preventing generic competition for up to 8 years from product registration.

AB8939 has also received orphan drug designation for AML by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). This orphan drug designation confers 10 and 7 years of marketing exclusivity in Europe and the US, respectively, from the date of the product registration.

References

[1] Humbert M, Letard S, Goubard A, et al. Identification of AB8939, a novel synthetic microtubule destabilizer and ALDH inhibitor that overcomes multidrug resistance in tumor cells as a drug candidate for the treatment of refractory acute myeloid leukemia. bioRxiv 2025.12.10.692519; doi: https://doi.org/10.64898/2025.12.10.692519.

[2] AB Science press release 30/07/2025. https://www.ab-science.com/ab-science-receives-regulatory-approval-from-european-countries-to-initiate-third-stage-of-phase-i-ii-study-combining-its-molecule-ab8939-with-venetoclax-for-the-treatment-of-aml/

About bioRxiv
BioRxiv (pronounced “bio-archive”) is a free online archive and distribution service for unpublished preprints in the life sciences. It is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. By posting preprints on bioRxiv, authors are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals.

About AB8939
AB8939 is a new synthetic molecule that targets cancer cells by destabilizing the microtubules essential for cell division and cancer stem cells by inhibiting enzymes (ALDH1A1 and ALDH2) essential for maintaining their physiological state and survival. The molecule ‘1-{4-[2-(5-ethoxymethyl-2-methylphenylamino)-oxazol-5-yl]phenyl}imidazolidin-2-one’ is the chemical name of AB8939. The intellectual property of AB8939 is 100% owned by AB Science.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action is key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short-term survival, or rare or refractory to previous lines of treatment.

AB Science has developed a proprietary portfolio of molecules, and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is being developed for human medicine in oncology, neurological diseases, inflammatory diseases, and viral diseases. The company is headquartered in Paris, France and is listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website: www.ab-science.com.

Forward-looking Statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment

• AB8939 bioRxiv vENG VF

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline




Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen Contacts

Investors
Henry Wheeler                henry.wheeler@ipsen.com        +33 764471149
Khalid Deojee                khalid.deojee@ipsen.com        +33 666019526

Media
Sally Bain                sally.bain@ipsen.com                +1 8573200517
Anne Liontas                 anne.liontas.ext@ipsen.com        +33 767347296

Disclaimers and/or forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

Attachment

• Ipsen PR_ImCheck Acquisition_15122025

Booking Health Releases 2026 Rankings of Germany’s Most Trusted Cancer Hospitals for International Patients




Booking Health Releases 2026 Rankings of Germany’s Most Trusted Cancer Hospitals for International Patients

Langenfeld, Germany, Dec. 15, 2025 (GLOBE NEWSWIRE) — Booking Health, a leading platform for international medical travel, announced today the release of its 2026 rankings of Germany’s most trusted cancer hospitals. These certified oncology centers are recognized for their advanced treatment options—including dendritic cell therapy, TACE, and electrochemotherapy—and continue to attract patients from around the world seeking high-quality, evidence-based cancer care.

Cancer Treatment in Germany

In 2026, Germany reaffirms its status as a global leader in oncology, providing patients from around the world with innovative medical care and access to modern cancer treatment protocols. German clinics demonstrate improved survival rates, therapeutic effectiveness and accessibility to high-tech procedures for international patients 一 according to the updated rankings of the top 10 cancer hospitals in Germany. Thanks to advanced methods, interdisciplinary teams, high-precision diagnostics and certified treatment programs cancer treatment in Germany 2026 is one of the most sought-after destinations for medical tourism.

German cancer centers offer a wide range of solutions 一 from standard chemotherapy and radiation therapy to innovative technologies (dendritic cell vaccines, TACE, electrochemotherapy and regional chemotherapy). That is why patients can receive the best cancer care in Germany. Patients from Europe, Asia, the USA and the Middle East are actively coming here looking for reliable, evidence-based and effective cancer treatment.

Why Patients Are Choosing Germany for Cancer Treatment in 2026?

Germany remains one of the most attractive destinations for international patients in 2026 (due to its high standards of medicine, advanced technology and proven clinical results). The country combines the latest treatments, powerful diagnostics and certified cancer centers 一 guaranteeing the effectiveness and safety.

Innovative Cancer Treatments in Germany

Germany offers new cancer treatment methods 2026 which increase the effectiveness of treatment and minimize side effects. 

• Dendritic cell therapy is one of the key innovative methods that stimulates the patient’s own immune system to recognize and destroy cancer cells.
• TACE (transarterial chemoembolization) is another important treatment method. It allows for accurate chemo delivery directly to the tumor, minimizing the systemic burden throughout the body. TACE is often combined with targeted therapy and modern immunotherapy programs.
• Electrochemotherapy is another example of an innovative approach. The combination of local electroporation and the introduction of chemotherapy drugs destroys tumor cells in the affected area without harming healthy tissues. This method is used for both superficial and internal tumors and is often included in complex therapy regimens.
• Regional chemotherapy provides local delivery of chemo to the vessels, that feed the tumor, achieving high concentrations in the affected area without systemic toxicity.

In addition to these methods German clinics actively use complex treatment protocols, combining chemotherapy and radiation therapy with targeted drugs and modern supportive therapy. Thanks to this, international patients receive advanced cancer therapy in Germany which guarantees high chances of successful treatment, safety and comfort during their stay in the clinic.

Modern Diagnostics and Treatment Planning

German clinics offer high-tech diagnostic methods, that allow doctors to obtain the most complete information about the tumor. Among them are new-generation PET-CT, 3T MRI, molecular tumor sequencing and 3D visualization for planning operations. This enables the optimal treatment strategy even in complex cases, increases the accuracy of surgical interventions and improves the patient’s prognosis.

Certified Oncology Centers

Leading German hospitals have the status of certified oncology clinics, confirmed by the German Oncology Society (DKG). This means, that the treatment meets the highest international standards.

Accessibility and Effectiveness of Treatment

German clinics offer affordable cancer care in Europe. Treatment here is often cheaper than in the US or UK, while the quality and technological level remain at the highest standards. This combination of innovation, safety and affordability makes Germany one of the most attractive destinations for international patients seeking effective and scientifically based cancer treatment.

Where to Treat Cancer in Germany

Germany maintains its status as one of the world leaders in oncology thanks to powerful cancer centers offering high-tech diagnostics, personalized treatment programs and advanced therapy methods. The cancer hospital rankings Germany help international patients choose reliable institutions for comprehensive treatment. Below is a description of the leading German oncology centers which combine scientific knowledge, practical experience and a high level of service.

• Helios Hospital Berlin-Buch, Berlin 一 is known as one of the leading centers for the treatment of both solid tumors and hematological diseases. The clinic specializes in bone marrow transplantation 一 more than 200 procedures each year and more than 1,500 patients receive treatment for sarcomas and soft tissue tumors annually. Clinic uses different innovative methods (dendritic cell vaccines, regional chemotherapy and others). Patients note the high quality of service, professionalism and comfortable conditions 一 this is confirmed by numerous cancer patient reviews.
• University Hospital RWTH Aachen, Aachen 一 this university center is known for its advanced treatment programs for colorectal cancer, rare tumors and complex oncological cases. Robotic surgery, modern radiotherapy and innovative protocols of advanced cancer therapy in Germany are actively used here. The center combines the latest scientific developments with practical application, which makes it one of the most popular specialized oncology hospitals for international patients.
• Hallwang Klinik, Dornstetten 一 Hallwang Klinik specializes in personalized cancer treatment with individual therapy regimens for patients with difficult-to-treat tumors. Here, classic chemotherapy is combined with immunotherapy, targeted therapy, regional chemotherapy and others. The clinic is known for its attention to the patient’s quality of life and early diagnosis. Thanks to this, the institution is in high demand among international patients and constantly receives positive cancer patient reviews.
• University Hospital of Ludwig Maximilian University of Munich, Munich 一 one of the oldest clinics in Germany, that offers comprehensive oncological care at all stages of the disease and actively implements the latest treatment methods (including dendritic cell vaccines and regional chemotherapy). The university hospital is known for its high survival rates and many years of scientific experience which makes it one of the best German oncology centers for international patients.
• Schön Klinik Rendsburg, Rendsburg 一 this clinic is distinguished by its individual approach to cancer treatment and prevention. It combines modern diagnostics with high-tech surgical and comprehensive therapeutic programs. International patients choose this center due to the high-quality service and the integration of innovative methods.
• University Hospital Rechts der Isar Munich, Munich 一 this hospital unites 33 specialized departments and cooperates with CCC Munich. The clinic combines research and clinical practice, offering a wide range of treatments (including pediatric oncology and complex cases). Patients from all over the world appreciate this center for its high level of professionalism and the opportunity to receive international cancer treatment of the highest standard.
• University Hospital Greifswald, Greifswald 一 a hospital with modern equipment, that treats more than 150,000 patients each year. The center specializes in nuclear medicine, bone marrow transplantation and palliative care. International patients note the high level of care, comprehensive treatment and positive cancer patient reviews (confirming the center’s status among the leading specialized oncology hospitals).
• Asklepios Hospital Barmbek Hamburg, Hamburg 一 this DKG-certified center specializes in the treatment of liver and lung cancer. The clinic has more than 1,600 medical staff and receives more than 36,000 inpatients annually. It uses modern methods of navigational and interventional oncology providing the best cancer care in Germany for international patients.
• University Hospital Tuebingen, Tübingen 一 first clinic in Germany with KTQ certification. The center serves more than 367,000 outpatients and 74,000 inpatients each year. Specializations include rare tumors, sarcomas and pediatric oncology. The clinic’s approach combines modern diagnostics with comprehensive treatment (making it one of the leading German oncology centers).
• Medias Cancer Clinic Burghausen, Burghausen 一 is known for its integrative approach to cancer treatment combining classical chemotherapy and radiation therapy with innovative therapies.

How Booking Health Helps International Patients

Many international patients choose Booking Health to receive comprehensive support during their cancer treatment in Germany. The service organizes consultations with leading specialists, selects a clinic according to the specific case, coordinates all stages of treatment and ensures comfort during the patient’s stay abroad.

Patients note, that Booking Health provides 24/7 support and guarantees a personalized approach. Thanks to this coordination, patients can focus on treatment (including dendritic cell vaccines, TACE, electrochemotherapy and regional chemotherapy) and achieve the best results. Booking Health support makes the treatment process more predictable, safe and comfortable.

About Booking Health

Booking Health™ is the international platform for rapid access to innovative treatments in the world’s leading certified clinics. Our network features over 250 top-tier hospitals across the globe, all distinguished by the exceptional levels of medical accreditation and expertise. By arranging care with the help of Booking Health company, you benefit from comprehensive medical support based on the latest innovations and personalized coordination. We offer cost saving up to 70% compared to direct booking via clinics — all without compromising on quality. Choosing Booking Health means more than just acquiring access to innovative world-class therapy – it means saving valuable time knowing that every detail is handled by professionals. Headquartered in Bad Hönningen, Germany and officially registered in Düsseldorf under HRB 106466, Booking Health proudly consults patients from over 75 countries for over a decade, offering services in 11 languages. 

Press inquiries

Booking Health
https://bookinghealth.com/
Lena Hanten
marketing@bookinghealth.com 

Face-Art Maestro Dr Jaffer Khan Pioneers Aesthetic Artistry for Advanced Plastic Surgery in Dubai




Face-Art Maestro Dr Jaffer Khan Pioneers Aesthetic Artistry for Advanced Plastic Surgery in Dubai

The Visionary Surgeon Who Uses Face Art Techniques to Sculpt Faces, Ensuring Timeless Harmony and Profound Confidence

DUBAI, United Arab Emirates, Dec. 15, 2025 (GLOBE NEWSWIRE) — In Dubai, Dr. Jaffer Khan is redefining plastic surgery, elevating it from a clinical process of alteration to a true art form. Hailed as a “Face-Art Maestro,” Dr. Khan approaches every patient not as a list of imperfections but as a canvas awaiting subtle refinement. His singular focus on advanced, natural results is setting a new aesthetic standard across the UAE and beyond, transforming cosmetic surgery into an exercise in high-end artistry.

Dr Khan’s methods are grounded in an understanding of proportion and symmetry. He applies principles such as the Golden Ratio to guide treatment plans, ensuring enhancements complement the existing features rather than alter them dramatically. His training and decades of experience across reputable institutions have shaped a practice built on measured improvement and predictable, realistic outcomes.

To achieve such artistic perfection, Dr. Khan employs only the most advanced techniques. He is renowned for his mastery in Facelifting, a revolutionary procedure that addresses underlying muscle structure rather than just tightening skin. This delivers a longer-lasting lift that eliminates the “Pulled” look, providing unparalleled facial rejuvenation. Similarly, his work in “Face Art”, a sophisticated combination of dermal Fillers and Anti-wrinkle injections, is marked by precision. Dr. Khan, a leading plastic surgeon in Dubai, specializes in sophisticated and complex revision surgeries, using his extensive experience to correct previous work and transform disappointment into desirable, beautiful outcomes. His focus remains unwavering: to enhance each patient’s natural beauty, never to erase it.

The patient experience with Dr Khan emphasizes consultation and communication. Treatment decisions are made collaboratively, with clear discussion on expected outcomes and long-term maintenance. His Dubai-based clinic features comprehensive facilities and a dedicated team to support patient safety and recovery throughout the process. Contact Aesthetics International, the leading plastic surgery clinic in Dubai, to explore how this artistic and meticulous approach can deliver sophisticated, natural, and enduring results that transform your confidence and well-being.

• Call: +971 4 384 5600
• Visit: https://aesthetics.ae
• Email: Info@aesthetics.ae

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/79b16bb4-a75b-4be8-b3eb-5c40575f23d5

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer




Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter.” Chang, W.-H.; Shah, D.; Myers, S.; Potts, M.; Qazi, S.; Trieu, V. International Journal of Molecular Sciences 2025, 26, 11920.

The study presents a comprehensive, data-driven analysis of two emerging biomarkers—DNMT3A (DNA methyltransferase 3A) and GMPS (guanine monophosphate synthetase)—across hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC). By integrating survival outcomes, transcriptomic profiling, and tumor microenvironment (TME) analyses from more than 7,000 patients, the authors demonstrate that the prognostic significance of these biomarkers is highly context-dependent, shaped by immune composition, metabolic reprogramming, and innate immune sensing pathways.

Training the Next Generation of Scientists

The publication also reflects the educational mission of the Brush and Key Foundation, which supports young scholars through mentored research experiences that bridge scientific inquiry, critical thinking, and professional development.

The paper’s author- Drashya Shah, an intern supported by the Brush and Key Foundation, shared the following reflection: “My experience working with the Brush and Key Foundation for Young Artists has been truly valuable and enriching. Throughout the research and writing process, I received consistent guidance and insightful feedback at every stage, which helped me refine my ideas and present my findings with clarity and precision. This collaborative environment not only strengthened the quality of my paper but also significantly boosted my confidence as a researcher. The skills and knowledge I gained through this journey are lifelong, and I will undoubtedly carry them forward into my future education and professional work. I am deeply grateful to everyone involved for their unwavering support and encouragement.”

“This work exemplifies how advanced bioinformatics, translational oncology, and structured mentorship can intersect to generate meaningful scientific insight,” said Dr. Vuong Trieu, co-author and contributor to the study. “Equally important, it demonstrates how hands-on research training helps prepare the next generation of scientists.”

Dr. Wen-Han Chang, corresponding author, added, “The work highlights why biomarkers cannot be interpreted in isolation. Tumor context—immune composition, metabolic state, and innate sensing—fundamentally alters prognostic meaning and therapeutic opportunity.”

About the Brush and Key Foundation

The Brush and Key Foundation is a nonprofit organization dedicated to mentoring and educating young scholars through hands-on research, structured guidance, and interdisciplinary learning. The foundation emphasizes critical thinking, scientific communication, and real-world research experience to help students build durable skills applicable to future academic and professional pursuits.

About Oncotelic

Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma “DIPG” (through OT-101) through its 45% joint venture, melanoma (through CA4P), and Acute Myeloid Leukemia “AML” (through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019.

Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease (“PD”). Over 60,000 new patients are being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics. AL-101 is also being developed for Erectile Dysfunction (“ED”). ED is the most prevalent male sexual disorder globally. The percentages of men affected by ED are as follows: 14.3-70% of men aged 60 years, 6.7-48% of men aged 70 years, and 38% of men aged 80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors. Through similar mechanism of action, AL-101 is being developed for Female Sexual Dysfunction (“FSD”). Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260-269). There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (“HSDD”) in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD – however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore, there is an urgent need for effective therapy against FSD and HSDD.

Oncotelic’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) that involve substantial risks and uncertainties. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “would,” “intend,” “target,” “aim,” “project,” “believe,” “estimate,” “predict,” “potential,” “seek,” “indicate,” or “continue” or the negative of these terms or other similar words, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future, such as our estimates regarding anticipated operating income or losses, future performance, future revenues and projected expense, including that to fund our clinical and other development programs; our liquidity and our expectations regarding our needs for and ability to raise additional capital; our ability to continue as a going concern; our ability to select and capitalize on commercially desirable product opportunities as a result of limited financial resources; our ability to manage our expenses effectively and raise the funds needed to continue our business; our ability to retain the services of our current or future executive officers, directors and principal consultants; the competitive nature of our industry and the possibility that our products or product candidates may become obsolete or may not generate revenues as expected or at all; our ability to obtain and maintain regulatory approval of our existing products and any future products we may develop; the development of and the process of commercializing AI/Blockchain and other technologies for supporting the development of OT- 101 and Artemisinin for COVID-19, OT-101, including development of OT-101, Artemisinin, OXi4503, CA4P and our 2021 in-licensing of apomorphine; the initiation, timing, progress and results of our preclinical and clinical trials, research and development programs; regulatory and legislative developments in the United States and foreign countries; the timing, costs and other limitations involved in obtaining regulatory approval for any product; the further preclinical or clinical development and commercialization of our product candidates; the entering into any corporate transactions to develop our products through partnerships, joint ventures or other corporate transactions; our ability to make a proposed initial public offering between us and our joint-venture partners for the joint venture, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof: building and the success of our nanoparticle platform and the related success of launching the platform; the expected valuation of the JV, and therefore a corresponding increase in the valuation of the Company, by virtue of it’s ownership in the JV; the success of the launch of Pet2DAO, a corporation with a DAO infrastructure, the success of Pet2DAO and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the tokens as registrable securities with the Securities and Exchange Commission (“SEC”) through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable; our ability to obtain and maintain orphan drug exclusivity for some of our product candidates; the potential benefits of our product candidates over other therapies; our ability to enter into and maintain any collaboration with respect to product candidates; our ability to continue to develop or commercialize our products or product candidates in the event any license agreements in place with third parties expire or are terminated; the performance and conduct of third parties, including our third-party manufacturers and third party service providers used in our clinical trials; our ability to obtain and maintain intellectual property protection for our products and operate our business without infringing upon the intellectual property rights of others; the potential liability exposure related to our products and our insurance coverage for such exposure; our ability to form alliances with other third parties to develop the products in our pipeline through partnerships, joint ventures, mergers or acquisitions; the successful development of our sales and marketing capabilities; the size and growth of the potential markets for our products and our ability to serve those markets; the rate and degree of market acceptance of any future products; the volatility of the price of our common stock; the ability to achieve secondary trading of our stock in certain states; the dilutive effects of potential future equity issuances; our expectation that no dividends will be declared on our common stock in the foreseeable future; our ability to maintain an effective system of internal controls; the payment and reimbursement methods used by private or governmental third-party payers; our ability to retain adequate staffing levels; unfavorable global economic conditions; unfavorable global epidemic and pandemic conditions; a failure of our internal computer systems or those of our contractors and consultants; potential misconduct or other improper activities by our employees, contractors or consultants; the ability of our business continuity and disaster recovery plans to protect us in the event of a natural disaster; and other factors discussed elsewhere in this document or any document incorporated by reference herein or therein.

Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline




Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies.

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Ipsen Contacts

Investors
Henry Wheeler                henry.wheeler@ipsen.com        +33 764471149
Khalid Deojee                khalid.deojee@ipsen.com        +33 666019526

Media
Sally Bain                sally.bain@ipsen.com                +1 8573200517
Anne Liontas                 anne.liontas.ext@ipsen.com        +33 767347296

Disclaimers and/or forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

Attachment

• Ipsen PR_ImCheck Acquisition_15122025

Booking Health Releases 2026 Rankings of Germany’s Most Trusted Cancer Hospitals for International Patients




Booking Health Releases 2026 Rankings of Germany’s Most Trusted Cancer Hospitals for International Patients

Langenfeld, Germany, Dec. 15, 2025 (GLOBE NEWSWIRE) — Booking Health, a leading platform for international medical travel, announced today the release of its 2026 rankings of Germany’s most trusted cancer hospitals. These certified oncology centers are recognized for their advanced treatment options—including dendritic cell therapy, TACE, and electrochemotherapy—and continue to attract patients from around the world seeking high-quality, evidence-based cancer care.

Cancer Treatment in Germany

In 2026, Germany reaffirms its status as a global leader in oncology, providing patients from around the world with innovative medical care and access to modern cancer treatment protocols. German clinics demonstrate improved survival rates, therapeutic effectiveness and accessibility to high-tech procedures for international patients 一 according to the updated rankings of the top 10 cancer hospitals in Germany. Thanks to advanced methods, interdisciplinary teams, high-precision diagnostics and certified treatment programs cancer treatment in Germany 2026 is one of the most sought-after destinations for medical tourism.

German cancer centers offer a wide range of solutions 一 from standard chemotherapy and radiation therapy to innovative technologies (dendritic cell vaccines, TACE, electrochemotherapy and regional chemotherapy). That is why patients can receive the best cancer care in Germany. Patients from Europe, Asia, the USA and the Middle East are actively coming here looking for reliable, evidence-based and effective cancer treatment.

Why Patients Are Choosing Germany for Cancer Treatment in 2026?

Germany remains one of the most attractive destinations for international patients in 2026 (due to its high standards of medicine, advanced technology and proven clinical results). The country combines the latest treatments, powerful diagnostics and certified cancer centers 一 guaranteeing the effectiveness and safety.

Innovative Cancer Treatments in Germany

Germany offers new cancer treatment methods 2026 which increase the effectiveness of treatment and minimize side effects. 

• Dendritic cell therapy is one of the key innovative methods that stimulates the patient’s own immune system to recognize and destroy cancer cells.
• TACE (transarterial chemoembolization) is another important treatment method. It allows for accurate chemo delivery directly to the tumor, minimizing the systemic burden throughout the body. TACE is often combined with targeted therapy and modern immunotherapy programs.
• Electrochemotherapy is another example of an innovative approach. The combination of local electroporation and the introduction of chemotherapy drugs destroys tumor cells in the affected area without harming healthy tissues. This method is used for both superficial and internal tumors and is often included in complex therapy regimens.
• Regional chemotherapy provides local delivery of chemo to the vessels, that feed the tumor, achieving high concentrations in the affected area without systemic toxicity.

In addition to these methods German clinics actively use complex treatment protocols, combining chemotherapy and radiation therapy with targeted drugs and modern supportive therapy. Thanks to this, international patients receive advanced cancer therapy in Germany which guarantees high chances of successful treatment, safety and comfort during their stay in the clinic.

Modern Diagnostics and Treatment Planning

German clinics offer high-tech diagnostic methods, that allow doctors to obtain the most complete information about the tumor. Among them are new-generation PET-CT, 3T MRI, molecular tumor sequencing and 3D visualization for planning operations. This enables the optimal treatment strategy even in complex cases, increases the accuracy of surgical interventions and improves the patient’s prognosis.

Certified Oncology Centers

Leading German hospitals have the status of certified oncology clinics, confirmed by the German Oncology Society (DKG). This means, that the treatment meets the highest international standards.

Accessibility and Effectiveness of Treatment

German clinics offer affordable cancer care in Europe. Treatment here is often cheaper than in the US or UK, while the quality and technological level remain at the highest standards. This combination of innovation, safety and affordability makes Germany one of the most attractive destinations for international patients seeking effective and scientifically based cancer treatment.

Where to Treat Cancer in Germany

Germany maintains its status as one of the world leaders in oncology thanks to powerful cancer centers offering high-tech diagnostics, personalized treatment programs and advanced therapy methods. The cancer hospital rankings Germany help international patients choose reliable institutions for comprehensive treatment. Below is a description of the leading German oncology centers which combine scientific knowledge, practical experience and a high level of service.

• Helios Hospital Berlin-Buch, Berlin 一 is known as one of the leading centers for the treatment of both solid tumors and hematological diseases. The clinic specializes in bone marrow transplantation 一 more than 200 procedures each year and more than 1,500 patients receive treatment for sarcomas and soft tissue tumors annually. Clinic uses different innovative methods (dendritic cell vaccines, regional chemotherapy and others). Patients note the high quality of service, professionalism and comfortable conditions 一 this is confirmed by numerous cancer patient reviews.
• University Hospital RWTH Aachen, Aachen 一 this university center is known for its advanced treatment programs for colorectal cancer, rare tumors and complex oncological cases. Robotic surgery, modern radiotherapy and innovative protocols of advanced cancer therapy in Germany are actively used here. The center combines the latest scientific developments with practical application, which makes it one of the most popular specialized oncology hospitals for international patients.
• Hallwang Klinik, Dornstetten 一 Hallwang Klinik specializes in personalized cancer treatment with individual therapy regimens for patients with difficult-to-treat tumors. Here, classic chemotherapy is combined with immunotherapy, targeted therapy, regional chemotherapy and others. The clinic is known for its attention to the patient’s quality of life and early diagnosis. Thanks to this, the institution is in high demand among international patients and constantly receives positive cancer patient reviews.
• University Hospital of Ludwig Maximilian University of Munich, Munich 一 one of the oldest clinics in Germany, that offers comprehensive oncological care at all stages of the disease and actively implements the latest treatment methods (including dendritic cell vaccines and regional chemotherapy). The university hospital is known for its high survival rates and many years of scientific experience which makes it one of the best German oncology centers for international patients.
• Schön Klinik Rendsburg, Rendsburg 一 this clinic is distinguished by its individual approach to cancer treatment and prevention. It combines modern diagnostics with high-tech surgical and comprehensive therapeutic programs. International patients choose this center due to the high-quality service and the integration of innovative methods.
• University Hospital Rechts der Isar Munich, Munich 一 this hospital unites 33 specialized departments and cooperates with CCC Munich. The clinic combines research and clinical practice, offering a wide range of treatments (including pediatric oncology and complex cases). Patients from all over the world appreciate this center for its high level of professionalism and the opportunity to receive international cancer treatment of the highest standard.
• University Hospital Greifswald, Greifswald 一 a hospital with modern equipment, that treats more than 150,000 patients each year. The center specializes in nuclear medicine, bone marrow transplantation and palliative care. International patients note the high level of care, comprehensive treatment and positive cancer patient reviews (confirming the center’s status among the leading specialized oncology hospitals).
• Asklepios Hospital Barmbek Hamburg, Hamburg 一 this DKG-certified center specializes in the treatment of liver and lung cancer. The clinic has more than 1,600 medical staff and receives more than 36,000 inpatients annually. It uses modern methods of navigational and interventional oncology providing the best cancer care in Germany for international patients.
• University Hospital Tuebingen, Tübingen 一 first clinic in Germany with KTQ certification. The center serves more than 367,000 outpatients and 74,000 inpatients each year. Specializations include rare tumors, sarcomas and pediatric oncology. The clinic’s approach combines modern diagnostics with comprehensive treatment (making it one of the leading German oncology centers).
• Medias Cancer Clinic Burghausen, Burghausen 一 is known for its integrative approach to cancer treatment combining classical chemotherapy and radiation therapy with innovative therapies.

How Booking Health Helps International Patients

Many international patients choose Booking Health to receive comprehensive support during their cancer treatment in Germany. The service organizes consultations with leading specialists, selects a clinic according to the specific case, coordinates all stages of treatment and ensures comfort during the patient’s stay abroad.

Patients note, that Booking Health provides 24/7 support and guarantees a personalized approach. Thanks to this coordination, patients can focus on treatment (including dendritic cell vaccines, TACE, electrochemotherapy and regional chemotherapy) and achieve the best results. Booking Health support makes the treatment process more predictable, safe and comfortable.

About Booking Health

Booking Health™ is the international platform for rapid access to innovative treatments in the world’s leading certified clinics. Our network features over 250 top-tier hospitals across the globe, all distinguished by the exceptional levels of medical accreditation and expertise. By arranging care with the help of Booking Health company, you benefit from comprehensive medical support based on the latest innovations and personalized coordination. We offer cost saving up to 70% compared to direct booking via clinics — all without compromising on quality. Choosing Booking Health means more than just acquiring access to innovative world-class therapy – it means saving valuable time knowing that every detail is handled by professionals. Headquartered in Bad Hönningen, Germany and officially registered in Düsseldorf under HRB 106466, Booking Health proudly consults patients from over 75 countries for over a decade, offering services in 11 languages. 

Press inquiries

Booking Health
https://bookinghealth.com/
Lena Hanten
marketing@bookinghealth.com 

Face-Art Maestro Dr Jaffer Khan Pioneers Aesthetic Artistry for Advanced Plastic Surgery in Dubai




Face-Art Maestro Dr Jaffer Khan Pioneers Aesthetic Artistry for Advanced Plastic Surgery in Dubai

The Visionary Surgeon Who Uses Face Art Techniques to Sculpt Faces, Ensuring Timeless Harmony and Profound Confidence

DUBAI, United Arab Emirates, Dec. 15, 2025 (GLOBE NEWSWIRE) — In Dubai, Dr. Jaffer Khan is redefining plastic surgery, elevating it from a clinical process of alteration to a true art form. Hailed as a “Face-Art Maestro,” Dr. Khan approaches every patient not as a list of imperfections but as a canvas awaiting subtle refinement. His singular focus on advanced, natural results is setting a new aesthetic standard across the UAE and beyond, transforming cosmetic surgery into an exercise in high-end artistry.

Dr Khan’s methods are grounded in an understanding of proportion and symmetry. He applies principles such as the Golden Ratio to guide treatment plans, ensuring enhancements complement the existing features rather than alter them dramatically. His training and decades of experience across reputable institutions have shaped a practice built on measured improvement and predictable, realistic outcomes.

To achieve such artistic perfection, Dr. Khan employs only the most advanced techniques. He is renowned for his mastery in Facelifting, a revolutionary procedure that addresses underlying muscle structure rather than just tightening skin. This delivers a longer-lasting lift that eliminates the “Pulled” look, providing unparalleled facial rejuvenation. Similarly, his work in “Face Art”, a sophisticated combination of dermal Fillers and Anti-wrinkle injections, is marked by precision. Dr. Khan, a leading plastic surgeon in Dubai, specializes in sophisticated and complex revision surgeries, using his extensive experience to correct previous work and transform disappointment into desirable, beautiful outcomes. His focus remains unwavering: to enhance each patient’s natural beauty, never to erase it.

The patient experience with Dr Khan emphasizes consultation and communication. Treatment decisions are made collaboratively, with clear discussion on expected outcomes and long-term maintenance. His Dubai-based clinic features comprehensive facilities and a dedicated team to support patient safety and recovery throughout the process. Contact Aesthetics International, the leading plastic surgery clinic in Dubai, to explore how this artistic and meticulous approach can deliver sophisticated, natural, and enduring results that transform your confidence and well-being.

• Call: +971 4 384 5600
• Visit: https://aesthetics.ae
• Email: Info@aesthetics.ae

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/79b16bb4-a75b-4be8-b3eb-5c40575f23d5

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer




Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation, today announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter.” Chang, W.-H.; Shah, D.; Myers, S.; Potts, M.; Qazi, S.; Trieu, V. International Journal of Molecular Sciences 2025, 26, 11920.

The study presents a comprehensive, data-driven analysis of two emerging biomarkers—DNMT3A (DNA methyltransferase 3A) and GMPS (guanine monophosphate synthetase)—across hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC). By integrating survival outcomes, transcriptomic profiling, and tumor microenvironment (TME) analyses from more than 7,000 patients, the authors demonstrate that the prognostic significance of these biomarkers is highly context-dependent, shaped by immune composition, metabolic reprogramming, and innate immune sensing pathways.

Training the Next Generation of Scientists

The publication also reflects the educational mission of the Brush and Key Foundation, which supports young scholars through mentored research experiences that bridge scientific inquiry, critical thinking, and professional development.

The paper’s author- Drashya Shah, an intern supported by the Brush and Key Foundation, shared the following reflection: “My experience working with the Brush and Key Foundation for Young Artists has been truly valuable and enriching. Throughout the research and writing process, I received consistent guidance and insightful feedback at every stage, which helped me refine my ideas and present my findings with clarity and precision. This collaborative environment not only strengthened the quality of my paper but also significantly boosted my confidence as a researcher. The skills and knowledge I gained through this journey are lifelong, and I will undoubtedly carry them forward into my future education and professional work. I am deeply grateful to everyone involved for their unwavering support and encouragement.”

“This work exemplifies how advanced bioinformatics, translational oncology, and structured mentorship can intersect to generate meaningful scientific insight,” said Dr. Vuong Trieu, co-author and contributor to the study. “Equally important, it demonstrates how hands-on research training helps prepare the next generation of scientists.”

Dr. Wen-Han Chang, corresponding author, added, “The work highlights why biomarkers cannot be interpreted in isolation. Tumor context—immune composition, metabolic state, and innate sensing—fundamentally alters prognostic meaning and therapeutic opportunity.”

About the Brush and Key Foundation

The Brush and Key Foundation is a nonprofit organization dedicated to mentoring and educating young scholars through hands-on research, structured guidance, and interdisciplinary learning. The foundation emphasizes critical thinking, scientific communication, and real-world research experience to help students build durable skills applicable to future academic and professional pursuits.

About Oncotelic

Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma “DIPG” (through OT-101) through its 45% joint venture, melanoma (through CA4P), and Acute Myeloid Leukemia “AML” (through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019.

Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease (“PD”). Over 60,000 new patients are being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics. AL-101 is also being developed for Erectile Dysfunction (“ED”). ED is the most prevalent male sexual disorder globally. The percentages of men affected by ED are as follows: 14.3-70% of men aged 60 years, 6.7-48% of men aged 70 years, and 38% of men aged 80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors. Through similar mechanism of action, AL-101 is being developed for Female Sexual Dysfunction (“FSD”). Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260-269). There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (“HSDD”) in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD – however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore, there is an urgent need for effective therapy against FSD and HSDD.

Oncotelic’s Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) that involve substantial risks and uncertainties. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “would,” “intend,” “target,” “aim,” “project,” “believe,” “estimate,” “predict,” “potential,” “seek,” “indicate,” or “continue” or the negative of these terms or other similar words, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future, such as our estimates regarding anticipated operating income or losses, future performance, future revenues and projected expense, including that to fund our clinical and other development programs; our liquidity and our expectations regarding our needs for and ability to raise additional capital; our ability to continue as a going concern; our ability to select and capitalize on commercially desirable product opportunities as a result of limited financial resources; our ability to manage our expenses effectively and raise the funds needed to continue our business; our ability to retain the services of our current or future executive officers, directors and principal consultants; the competitive nature of our industry and the possibility that our products or product candidates may become obsolete or may not generate revenues as expected or at all; our ability to obtain and maintain regulatory approval of our existing products and any future products we may develop; the development of and the process of commercializing AI/Blockchain and other technologies for supporting the development of OT- 101 and Artemisinin for COVID-19, OT-101, including development of OT-101, Artemisinin, OXi4503, CA4P and our 2021 in-licensing of apomorphine; the initiation, timing, progress and results of our preclinical and clinical trials, research and development programs; regulatory and legislative developments in the United States and foreign countries; the timing, costs and other limitations involved in obtaining regulatory approval for any product; the further preclinical or clinical development and commercialization of our product candidates; the entering into any corporate transactions to develop our products through partnerships, joint ventures or other corporate transactions; our ability to make a proposed initial public offering between us and our joint-venture partners for the joint venture, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof: building and the success of our nanoparticle platform and the related success of launching the platform; the expected valuation of the JV, and therefore a corresponding increase in the valuation of the Company, by virtue of it’s ownership in the JV; the success of the launch of Pet2DAO, a corporation with a DAO infrastructure, the success of Pet2DAO and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the tokens as registrable securities with the Securities and Exchange Commission (“SEC”) through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable; our ability to obtain and maintain orphan drug exclusivity for some of our product candidates; the potential benefits of our product candidates over other therapies; our ability to enter into and maintain any collaboration with respect to product candidates; our ability to continue to develop or commercialize our products or product candidates in the event any license agreements in place with third parties expire or are terminated; the performance and conduct of third parties, including our third-party manufacturers and third party service providers used in our clinical trials; our ability to obtain and maintain intellectual property protection for our products and operate our business without infringing upon the intellectual property rights of others; the potential liability exposure related to our products and our insurance coverage for such exposure; our ability to form alliances with other third parties to develop the products in our pipeline through partnerships, joint ventures, mergers or acquisitions; the successful development of our sales and marketing capabilities; the size and growth of the potential markets for our products and our ability to serve those markets; the rate and degree of market acceptance of any future products; the volatility of the price of our common stock; the ability to achieve secondary trading of our stock in certain states; the dilutive effects of potential future equity issuances; our expectation that no dividends will be declared on our common stock in the foreseeable future; our ability to maintain an effective system of internal controls; the payment and reimbursement methods used by private or governmental third-party payers; our ability to retain adequate staffing levels; unfavorable global economic conditions; unfavorable global epidemic and pandemic conditions; a failure of our internal computer systems or those of our contractors and consultants; potential misconduct or other improper activities by our employees, contractors or consultants; the ability of our business continuity and disaster recovery plans to protect us in the event of a natural disaster; and other factors discussed elsewhere in this document or any document incorporated by reference herein or therein.

Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com